Meta-analysis Of Shenyan Kangfu Tablets Combined With ARB Antihypertensive Drugs In The Treatment Of Chronic Nephritis

Objective This article mainly analyzes and discusses Shenyan Kangfu Tablets combined with ARB antihypertensive drugs,and explores the treatment situation through case studies.The analysis of nephritis rehabilitation tablets combined with ARB-type antihypertensive drugs and western medicine alone in improving clinical symptoms,reducing urinary protein content,and clearing blood creatinine through comparative research methods can provide a certain future research on the relevant treatment of chronic nephritis SignificanceMethods The main research method selected was literature search.Through the entry of keywords,relevant existing studies on kidney inflammation rehabilitation tablets combined with ARB antihypertensive drugs chronic nephritis were selected.The relevant inclusion criteria and exclusion conditions were set to meet the requirements.The relevant literature of this study was used to organize the data and extract the data.The software selected for the experiment was RevMan5.3.For the analysis of the corresponding symptoms of the patients after receiving the treatment,observe the 24-hour urine protein and serum creatinine and perform a Meta analysis.Finally,the research results are obtained.Conclusion Based on a literature search,a Meta-analysis of the nephritis rehabilitation tablets combined with ARB antihypertensive drugs was conducted,and the main conclusions were as follows:(1)In the treatment of nephritis rehabilitation tablets combined with ARB drugs,regarding the therapeutic effect of urinary protein,nephritis rehabilitation tablets.the effect of combined ARB drugs is better than that of ARB drugs alone;(2)In terms of reducing blood creatinine in patients with chronic nephritis,the effect of Shenyan Kangfu Tablets combined with ARB drugs compared with ARB drugs alone has better practical significance;(3)total In terms of effectiveness,the total effective rate of Shenyan Kangfu Tablets combined with ARB drugs in treating chronic nephritis is higher than that of ARB drugs alone.